Clinical Trial

MRI T2 Lesion Burden in Multiple Sclerosis: A Plateauing Relationship with Clinical Disability

Type: 
Journal
Year: 
2006
Authors: 
Li DKB, Held U., Petkau J., Daumer M., Barkhof F., Fazekas F., Frank JA., Kappos L., Miller DH., Simon JH., Wolinsky JS., Filippi M.: Neurology 66, p. 1384-1389

Monthly i.v. methylprednisolone in relapsing-remitting MS - Reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations

Type: 
Journal
Year: 
2006
Authors: 
Then Bergh F., Kumpfel T., Schumann E., Held U., Schwan M., Blazevic M., Wismuller A., Holsboer F., Yassouridis A., Uhr M., Weber F., Daumer M., Trenkwalder C. and Auer DP.: BMC Neurology 6: 19

Immunmodulatorische Stufentherapie der Multiplen Sklerose. Aktuelle Therapieempfehlungen (September 2006)

Type: 
Journal
Year: 
2006
Authors: 
Multiple Sklerose Therapie Konsensus Gruppe (MSTKG) und Peter Riekmann: Der Nervenarzt 77, 1506–1518

A randomised, double-blind, placebo-controlled study of oral hydrolytic enzymes in relapsing multiple sclerosis

Type: 
Journal
Year: 
2005
Authors: 
Baumhackl U., Kappos L., Radue E.W., Freitag P., Guseo A., Daumer M., Mertin J.: Multiple Sclerosis 11: 166-168

Predicting gadolinium-enhancement status in MS patients eligible for randomized clinical trials.

Type: 
Journal
Year: 
2005
Authors: 
Barkhof F., Held U., Petkau J., Menzler S., Simon J., Daumer M., et al: Neurology 65, p. 1447-1454
Syndicate content